Novavax, Inc. [NASDAQ: NVAX] traded at a high on 10/31/23, posting a 2.15 gain after which it closed the day’ session at $6.66. The company report on October 31, 2023 at 4:37 PM that Novavax’s Updated COVID-19 Vaccine Now Approved in the EU.
Novavax’s updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Novavax is working closely with EU member states to bring its updated COVID-19 vaccine to those that have requested doses through the advance purchase agreement.
The results of the trading session contributed to over 5597341 shares changing hands. Over the past one week, the price volatility of Novavax, Inc. stands at 5.33% while the volatility over the past one month is 7.87%.
The market cap for NVAX stock reached $628.70 million, with 94.40 million shares outstanding and 87.57 million shares in the current float. Compared to the average trading volume of 9.92M shares, NVAX reached a trading volume of 5597341 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Novavax, Inc. [NVAX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $20.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for Novavax, Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 09, 2023.
The Average True Range (ATR) for Novavax, Inc. is set at 0.49, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 0.39.
How has NVAX stock performed recently?
Novavax, Inc. [NVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.56. With this latest performance, NVAX shares dropped by -6.06% in over the last four-week period, additionally sinking by -5.40% over the last 6 months – not to mention a drop of -71.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 46.79, with the RSI for the last a single of trading hit 50.36, and the three-weeks RSI is set at 46.06 for Novavax, Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 7.47, while it was recorded at 6.44 for the last single week of trading, and 8.04 for the last 200 days.
Novavax, Inc. [NVAX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novavax, Inc. [NVAX] shares currently have an operating margin of -32.53 and a Gross Margin at +54.46. Novavax, Inc.’s Net Margin is presently recorded at -33.20.
Reflecting on the efficiency of the workforce at the company, Novavax, Inc. [NVAX] managed to generate an average of -$330,291 per employee. Receivables Turnover for the company is 7.38 with a Total Asset Turnover recorded at a value of 0.82.Novavax, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.69 and a Current Ratio set at 0.71.
Insider trade positions for Novavax, Inc. [NVAX]
The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in NVAX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in NVAX stock with ownership which is approximately 5.7994%.
